PT-001 (Pandion Therapeutics)

N/A

Report date: 2024/12/03 17:40:07

Base Information

Drug NamePT-001 (Pandion Therapeutics)
Drug Alias NamePT-001 (Pandion Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 agonistsAntii-MADCAM1
TargetsProgrammed cell death protein 1Mucosal addressin cell adhesion molecule-1
Therapy Area/IndicationsDiabetes Mellitus, Type 1Autoimmune Diseases of the Nervous System
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPandion TherapeuticsMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesPandion Therapeutics
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1Autoimmune Diseases of the Nervous System
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A